Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →Filing growth compares 2021 (103 records) with 2024 (45) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 1,128 records in scope (CR5), not by the ranked leaders only.
Engineered bacteria as therapeutics spans strains built to secrete a payload, persist in a host niche, or shut themselves down on command. The search set pulls records that combine an engineered-bacterium or biocontainment claim with a functional control mechanism — payload secretion, kill-switch reliability, horizontal transfer risk, colonization persistence, inducible expression, or containment efficiency. That pairing is deliberate: it separates strains built as delivery platforms from the broader genetic-engineering literature that never addresses safety or control.
The scope runs from 2015 through the 2026-07-31 cut-off, covering 1,128 published records. Because publication typically lags filing by around 18 months, the most recent one to two years understate actual filing activity and should be read as still filling in.
Pick a task. Every answer cites the patents behind it.
Two views of the same 1,128 records: how filing activity has moved year over year, and which IPC subclasses carry the claims.
Filings rose to a peak of 123 in 2020, then declined; the 2021-to-2024 span (the last year treatable as complete) fell 56%, from 103 to 45. Years after 2024 are still incomplete due to publication lag and should not be read as a continuation of that decline.
C12N (microorganisms and genetic engineering) appears on 82.9% of records and A61K (medicinal preparations) on 55.1%, confirming the corpus is dominated by strain construction and formulation claims rather than diagnostic or analytical work — C12Q and G01N each sit below 7%. Because records carry multiple classes, these shares sum to well over 100%.
Shares are the percentage of the 1,128 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
This page is one run against one query. Ask Eureka your own question about engineered bacteria as therapeutics and every answer comes back with the patent numbers behind it.
Try EurekaGenetically engineered bacteria, pharmaceutical compositions thereof, and methods of attenuating metabolic diseases are disclosed.Filed by Synlogic Operating Company, published 2019-01-10 — illustrative of the strain-plus-pharmaceutical-composition claim structure that recurs across the leading assignees in this dataset.


| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5508192A | Bacterial host strains for producing proteolytically sensitive polypeptides | 845 |
| 2 | US6433252B1 | Maize L3 oleosin promoter | 570 |
| 3 | US5514578A | Polynucleotides encoding insect steroid hormone receptor polypeptides and cells transformed with same | 310 |
| 4 | US7763420B2 | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders | 246 |
| 5 | WO1996037609A1 | A gene switch comprising an ecdysone receptor | 218 |
| 6 | US6245531B1 | Polynucleotide encoding insect ecdysone receptor | 210 |
| 7 | US6379945B1 | Gene switch | 205 |
| 8 | US6307123B1 | Methods and compositions for transgene identification | 130 |
| 9 | US7820184B2 | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders | 126 |
| 10 | US20080193373A1 | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders | 126 |
Citation counts favour older filings that have had more time to accumulate citations within the searched corpus; treat them as a signal of influence rather than of current commercial weight.
Each row carries its publication number; clicking a row searches Eureka by that number.
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Three patterns stand out once the records are grouped by assignee, technology class and receiving office.
The top 5 assignees hold 565 of the 1,128 records in scope, and the top 10 combined hold 689 (61.1%). That leaves a long tail of single- or few-filing entrants competing for the remaining claim space rather than a broad, even spread of activity.
Filings peaked at 123 in 2020 and declined to 45 by 2024, a 56% drop across the 2021-2024 span. Years beyond 2024 are still incomplete due to publication lag and should not be read as continuing the decline.
C12N (microorganisms and genetic engineering) and A61K (medicinal preparations) dominate the corpus at 82.9% and 55.1% of records respectively, while measurement-adjacent classes C12Q and G01N sit at 6.3% and 4.0%. The imbalance suggests analytical and monitoring claims around these strains remain comparatively open.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to engineered bacteria as therapeutics, with the prior art for and against each one.
The leader files well ahead of the field, and a small number of institutional pairs account for most of the co-filing activity.
The leading assignee holds 160 records against 44 at fifth place and 20 at tenth — a steep drop-off that marks this as a field with one dominant filer rather than several evenly matched ones.
Ten co-assignee pairs appear in the dataset. The strongest, an MIT-Broad Institute pairing, spans 136 shared records — far ahead of the next pairs, which sit in the single digits, indicating most collaboration is concentrated in one long-running partnership.
Several of the more active historical filers show sharp year-on-year declines in the most recent year — MIT down 86%, Broad Institute down 88%, and others at or near zero filings. Given publication lag, this should be read as an incomplete latest year rather than a confirmed pullback.
| Assignee | Recent year | YoY |
|---|---|---|
| Massachusetts Institute of Technology (MIT) | 1 | -86% |
| The Broad Institute, Inc. | 1 | -88% |
| Synlogic Operating Company, Inc. | 1 | -50% |
| Actym Therapeutics, Inc. | 0 | -100% |
| Synlogic, Inc. | 0 | — |
| Duke University | 0 | — |
| Hervana | 0 | — |
| Yeda Research and Development Co. Ltd. | 0 | -100% |
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, portfolio strategy, or spotting open claim space.
With half the field held by five assignees, any new filing in strain construction or delivery should be checked against their claim scope before drafting.
Run a freedom-to-operate check in EurekaThe MIT-Broad Institute pairing alone spans 136 shared records; watching how such pairs extend their claims signals where the next dense filing cluster will form.
Monitor assignee activity in EurekaContainment efficiency and horizontal transfer risk assays sit well behind core strain-engineering claims in filing density, suggesting room for a first-mover claim.
Explore white space in EurekaOne assignee leads clearly with 160 records, well ahead of the fifth-ranked filer at 44 and the tenth at 20. The top 5 assignees together hold 565 of the 1,128 records in scope, or 50.1%, and the top 10 hold 61.1%. Beyond that concentrated group, the ranking runs into a long tail of assignees with only a handful of filings each, so the field is best described as having one dominant filer plus a fragmented rest rather than several evenly matched competitors.
Filing peaked in 2020 at 123 records and fell to 45 by 2024, a 56% decline across that 2021-2024 span — the most recent period that publication lag allows us to treat as complete. Records from 2025 and 2026 are still incomplete because publication typically lags actual filing by around 18 months, so they should not be read as evidence the decline is continuing. The honest read is that activity cooled from its 2020 peak through 2024; anything more recent is still filling in.
This Synlogic Operating Company filing, published 2019-01-10, covers genetically engineered bacteria along with pharmaceutical compositions containing them and methods of using them to attenuate metabolic diseases. It is representative of a claim pattern seen repeatedly among the leading assignees in this dataset: pairing a specific engineered strain with a pharmaceutical composition and a therapeutic method, rather than claiming the engineering technique alone. Anyone designing a metabolic-disease strain therapy should read its granted claims closely before finalizing a delivery or dosing approach that overlaps this composition-and-method structure.
Measurement and analytical classes are thin relative to the core engineering claims: C12Q (enzyme/DNA testing) appears on only 6.3% of records and G01N (material analysis) on 4.0%, against 82.9% for C12N and 55.1% for A61K. Sub-areas such as containment efficiency measurement, horizontal transfer risk assays, and kill-switch reliability testing methods sit behind the core strain-construction claims in filing density. That gap suggests measurement and validation methods around these engineered strains remain comparatively open for a first claim, even where the underlying strain constructs are heavily claimed.
The United States receives the largest share of filings at 364 records, followed by the WIPO/PCT route at 250 and the European Patent Office at 165. Australia, Israel, and Canada follow at 88, 52, and 44 respectively. The heavy US and PCT presence indicates most applicants are pursuing broad international protection rather than filing narrowly in a single jurisdiction, consistent with a field led by well-resourced institutional and biotech assignees.
Go past this page: query the whole engineered bacteria as therapeutics corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.
Help us improve
Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.
This page